Reports Q4 revenue $1.03M, consensus $1.68M. As of December 31, 2018, cash, cash equivalents and investments were $494.0M, as compared to $673m.4M as of December 31, 2017. This decrease was primarily related to cash used in operating activities, partially offset by the $40.0 upfront payment received in connection with entering into the collaboration with CStone Pharmaceuticals and the $10.0M milestone payment achieved under the Roche collaboration in June 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.